Cargando…

Introduction: Ongoing clinical challenges in the management of meningiomas and future directions

Detalles Bibliográficos
Autores principales:	Wang, Justin Z, Nassiri, Farshad, Aldape, Kenneth, Zadeh, Gelareh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243837/ https://www.ncbi.nlm.nih.gov/pubmed/37287579 http://dx.doi.org/10.1093/noajnl/vdad030

Ejemplares similares

The multiomic landscape of meningiomas: a review and update
por: Wang, Justin Z., et al.
Publicado: (2023)

Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression
por: Karimi, Shirin, et al.
Publicado: (2020)

ECOA-8. Lung adenocarcinoma brain metastasis prediction using tumor DNA methylation profiling
por: Zuccato, Jeffrey, et al.
Publicado: (2021)

Special issue: advances in the multimodality management of brain metastases and ongoing approaches to further improve their treatment
por: Zuccato, Jeffrey A, et al.
Publicado: (2021)

How to live with a meningioma: experiences, symptoms, and challenges reported by patients
por: Nassiri, Farshad, et al.
Publicado: (2020)

DNA methylation profiling of a lipomatous meningioma: illustrative case
por: Patel, Zeel, et al.
Publicado: (2023)

The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care
por: Karimi, Shirin, et al.
Publicado: (2019)

The Evolving Role of Radiosurgery in the Management of Radiation-Induced Meningiomas: A Review of Current Advances and Future Directions
por: Mansouri, Alireza, et al.
Publicado: (2014)

Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2?
por: Behling, Felix, et al.
Publicado: (2023)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
por: Karimi, Shirin, et al.
Publicado: (2021)

COMPREHENSIVE MULTIPLATFORM ANALYSIS OF CDKN2A ALTERATIONS IN MENINGIOMAS
por: Wang, Justin Z, et al.
Publicado: (2023)

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas
por: Wang, Justin Z., et al.
Publicado: (2023)

Dendritic cell vaccines for high-grade gliomas
por: Eagles, Matthew E, et al.
Publicado: (2018)

The management of incidental meningioma: An unresolved clinical conundrum
por: Islim, Abdurrahman I, et al.
Publicado: (2023)

Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas
por: Wang, Justin Z., et al.
Publicado: (2023)

Outcomes and predictors of response to fractionated radiotherapy as primary treatment for intracranial meningiomas
por: Wang, Justin Z., et al.
Publicado: (2023)

Current and Future Directions in MS Management: Key Considerations for Managed Care Pharmacists
por: Lipsy, Robert J., et al.
Publicado: (2009)

Special issue: a contemporary landscape of the clinical and biological research in neurofibromatosis type 1
por: Suppiah, Suganth, et al.
Publicado: (2020)

Multiple meningiomas: Epidemiology, management, and outcomes
por: Fahlström, Andreas, et al.
Publicado: (2023)

NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas
por: Voisin, Mathew, et al.
Publicado: (2021)

The clinical and genomic features of seizures in meningiomas
por: Dincer, Alper, et al.
Publicado: (2023)

Artificial Intelligence, Radiomics, and Deep Learning in Neuro-Oncology
por: Galldiks, Norbert, et al.
Publicado: (2021)

Spinal meningiomas
por: Hohenberger, Christoph, et al.
Publicado: (2023)

Meningioma in the elderly
por: Amoo, Michael, et al.
Publicado: (2023)

Management of cutaneous neurofibroma: current therapy and future directions
por: Chamseddin, Bahir H, et al.
Publicado: (2019)

Clinical value of methylation testing: a case report of intraventricular schwannomas with associated molecular findings
por: Wang, Justin Z, et al.
Publicado: (2020)

Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care
por: Djuric, Ugljesa, et al.
Publicado: (2017)

OTHR-09. IDENTIFYING EPIGENETIC SIGNATURES IN LUNG ADENOCARCINOMAS THAT PREDICT DEVELOPMENT OF BRAIN METASTASIS
por: Zuccato, Jeffrey, et al.
Publicado: (2019)

Radiotherapy and radiosurgery for meningiomas
por: Chen, William C, et al.
Publicado: (2023)

A molecularly integrated grade for meningioma
por: Driver, Joseph, et al.
Publicado: (2021)

Clinical management of seizures in patients with meningiomas: Efficacy of surgical resection for seizure control and patient-tailored postoperative anti-epileptic drug management
por: Peart, Rodeania, et al.
Publicado: (2023)

Renin-Angiotensin Aldosterone System and Hypertension: Current Approaches and Future Directions
por: Flack, John M., et al.
Publicado: (2007)

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
por: Pineda, Estela, et al.
Publicado: (2023)

Introduction
por: Ross, Jonathan D C, et al.
Publicado: (2011)

Introduction
por: McGill, Janet
Publicado: (2018)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community
por: Aldape, Kenneth, et al.
Publicado: (2017)

Current and future management approaches for rheumatoid arthritis
por: Breedveld, Ferdinand C
Publicado: (2002)

The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis
por: Gregory, Grace E, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hqtpdq6voldj29ro578ptkucpr